# Shanghai Hengrui Pharmaceutical Co., Ltd. trials: 61 (2026)

ClinicalTrials.gov lists 61 trials with Shanghai Hengrui Pharmaceutical Co., Ltd. as lead sponsor, 23 of them recruiting or not yet recruiting.

## The full list

Clinical trials led by Shanghai Hengrui Pharmaceutical Co., Ltd.: 61 rows for $5, every trial on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/shanghai-hengrui-pharmaceutical-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 61
- Recruiting or not yet: 23
- Read on: November 19, 2026

## Trials

The 25 newest of 61, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 30, 2026 | NCT07906691 | A Study to Assess the Effect of Itraconazole on the Pharmacokinetics of HRS-4642 Following Intravenous Infusion in Healthy Participants | Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | Pancreatic Cancer | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07906691) |
| October 28, 2026 | NCT07900789 | HRS-4642 Combined With Antitumor Agents for the Treatment of Perioperative Pancreatic Cancer | Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Systemic Treatment-naïve Pancreatic Cancer | 825 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07900789) |
| September 2, 2026 | NCT07798947 | A Phase II Clinical Study of SHR-7787 Injection Combined With SHR-1316 Injection in Patients With LS-SCLC | Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 2 | Recruiting | Limited-stage Small-cell Lung Cancer | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07798947) |
| March 24, 2026 | NCT07490613 | A Phase I Study of SHR-3836 in Patients With Multiple Myeloma | Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 1 | Recruiting | Multiple Myeloma | 99 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07490613) |
| December 24, 2025 | NCT07301333 | A Study of Single and Multiple Doses of HRS-6257 in Healthy Subjects | Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 1 | Completed | Pain | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07301333) |
| December 22, 2025 | NCT07296341 | HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors | Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 1/2 | Recruiting | Locally Advanced or Metastatic Pancreatic Cancer With | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07296341) |
| December 5, 2025 | NCT07268040 | A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors | Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 2 | Recruiting | Malignant Solid Tumors | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07268040) |
| November 17, 2025 | NCT07229729 | A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer | Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 2 | Recruiting | Non-small Cell Lung Cancer | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07229729) |
| November 17, 2025 | NCT07229586 | A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors | Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 1/2 | Recruiting | Solid Tumor | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07229586) |
| July 18, 2025 | NCT07073534 | Phase I/II Clinical Study of SHR-1501 Combined With Adbelizumab in Patients With Malignant Tumors | Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 1/2 | Recruiting | Patients With Advanced or Metastatic Malignant Tumors | 203 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07073534) |
| March 26, 2025 | NCT06895928 | A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors | Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 2 | Recruiting | Advanced Solid Tumors | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06895928) |
| March 14, 2025 | NCT06877247 | A Mass Balance Study of \[14C\] SHR6508 in Chinese Hemodialysis Subjects With Secondary Hyperparathyroidism | Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 1 | Completed | Secondary Hyperparathyroidism | 5 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06877247) |
| December 17, 2024 | NCT06738251 | A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma | Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 3 | Recruiting | Advanced Urothelial Carcinoma | 402 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06738251) |
| November 26, 2024 | NCT06704828 | A Phase II Study of SHR-4602 as Montherapy or in Combination With Other Anti-tumor Therapies in Advanced Solid Tumors | Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 2 | Not yet recruiting | Advanced Solid Tumors | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06704828) |
| October 23, 2024 | NCT06654440 | A Trial of SHR-A2102 for Treatment of Advanced Gynecological Malignancy | Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 2 | Unknown | Advanced Gynecological Malignancy | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06654440) |
| October 18, 2024 | NCT06649292 | SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or Metastatic Gastric... | Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 3 | Recruiting | Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | 524 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06649292) |
| October 15, 2024 | NCT06639347 | A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma | Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 1/2 | Recruiting | Advanced Urothelial Carcinoma | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06639347) |
| September 20, 2024 | NCT06605222 | A Trial of SHR-7787 Injection in Patients With Advanced Solid Tumors | Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 1/2 | Recruiting | Advanced Solid Tumors | 201 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06605222) |
| September 19, 2024 | NCT06589778 | A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 1/2 | Unknown | Non-Small Cell Lung Cancer | 124 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06589778) |
| July 22, 2024 | NCT06512051 | A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer | Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 1/2 | Recruiting | Advanced or Metastatic Non-small Cell Lung Cancer | 248 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06512051) |
| July 19, 2024 | NCT06509958 | Phase Ⅱ Study of Adductor Canal Block With HR18034 for Postsurgical Pain Management in TKA | Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 2 | Terminated | Postoperative Pain Management in Total Knee Arthroplasty | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06509958) |
| June 25, 2024 | NCT06474468 | A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Esophageal Cancer | Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 1/2 | Unknown | Advanced or Metastatic Esophageal Cancer | 148 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06474468) |
| June 25, 2024 | NCT06474455 | A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors | Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 1/2 | Recruiting | Advanced Solid Tumors | 156 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06474455) |
| June 3, 2024 | NCT06439589 | Phase Ib/II Study of HRS2398 in Combination With Adebrelimab in Patients With Advanced Solid Tumors | Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 1/2 | Unknown | Advanced Solid Tumors | 88 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06439589) |
| May 30, 2024 | NCT06434961 | The Trial of SHR6508 in Secondary Hyperparathyroidism | Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 3 | Completed | Secondary Hyperparathyroidism | 498 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06434961) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 24 |
| Phase 1/2 | 14 |
| Phase 2 | 17 |
| Phase 3 | 6 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 21 |
| Recruiting | 20 |
| Unknown | 11 |
| Terminated | 4 |
| Not yet recruiting | 3 |
| Active not recruiting | 2 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Hyperparathyroidism, Secondary | 5 |
| Alzheimer Disease | 3 |
| Carcinoma, Non-Small-Cell Lung | 3 |
| Asthma | 3 |
| Lymphoma, B-Cell | 2 |
| Esophageal Neoplasms | 1 |
| Neoplasms | 1 |
| Pancreatic Neoplasms | 1 |
| Pain | 1 |
| Small Cell Lung Carcinoma | 1 |
| Multiple Myeloma | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Pediatric dentistry practices in the United States](https://specstream.ai/data/businesses/pediatric-dentistry-practices/united-states)
- [Hepatology practices in the United States](https://specstream.ai/data/businesses/hepatology-practices/united-states)
- [Cleaning companies in the United States](https://specstream.ai/data/businesses/cleaning-companies/united-states)
- [Web hosting companies in the United States](https://specstream.ai/data/businesses/web-hosting-companies/united-states)
- [Preschools in the United States](https://specstream.ai/data/businesses/preschools/united-states)
